

Document downloaded from:

<http://hdl.handle.net/10251/148015>

This paper must be cited as:

Ressler, A.; Ródenas Rochina, J.; Ivankovic, M.; Ivankovic, H.; Rogina, A.; Ferrer, G. (2018). Injectable chitosan-hydroxyapatite hydrogels promote the osteogenic differentiation of mesenchymal stem cells. *Carbohydrate Polymers*. 197:469-477.  
<https://doi.org/10.1016/j.carbpol.2018.06.029>



The final publication is available at

<https://doi.org/10.1016/j.carbpol.2018.06.029>

Copyright Elsevier

Additional Information

# Injectable chitosan-hydroxyapatite hydrogels promote the osteogenic differentiation of mesenchymal stem cells

Antonia Ressler<sup>a,\*</sup>, Joaquín Ródenas-Rochina<sup>b</sup>, Marica Ivanković<sup>a</sup>, Hrvoje Ivanković<sup>a</sup>, Anamarija Rogina<sup>a</sup>, Gloria Gallego Ferrer<sup>b,c</sup>

<sup>a</sup> Faculty of Chemical Engineering and Technology, University of Zagreb, HR-10001 Zagreb, Marulićev trg 19, p.p.177, Croatia

<sup>b</sup> Centre for Biomaterials and Tissue Engineering, Universitat Politècnica de València, Camino de Vera s/n, 46022 Valencia, Spain

<sup>c</sup> Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Valencia, Spain

\*Corresponding author: Antonia Ressler, Faculty of Chemical Engineering and Technology, University of Zagreb, HR-10001 Zagreb, Marulićev trg 19, p.p.177, Croatia, Tel: +385 01 4597 210, e-mail: [aressler@fkit.hr](mailto:aressler@fkit.hr)

E-mail addresses: [aressler@fkit.hr](mailto:aressler@fkit.hr) (A. Ressler), [jrodenasr@gmail.com](mailto:jrodenasr@gmail.com) (J. Ródenas Rochina), [mivank@fkit.hr](mailto:mivank@fkit.hr) (M. Ivanković), [hivan@fkit.hr](mailto:hivan@fkit.hr) (H. Ivanković), [arogina@fkit.hr](mailto:arogina@fkit.hr) (A. Rogina), [ggallego@ter.upv.es](mailto:ggallego@ter.upv.es) (G. Gallego Ferrer).

28 **Abstract**

29           Injectable hydrogels have emerged as promising biomaterials for tissue engineering  
30 applications. The goal of this study was to evaluate the potential of a pH-responsive chitosan-  
31 hydroxyapatite hydrogel to be used as a three-dimensional support for encapsulated  
32 mesenchymal stem cells (MSCs) osteogenic differentiation. *In vitro* enzymatic degradation of  
33 the hydrogel, during 28 days of incubation, in simulated physiological conditions, was  
34 characterized by swelling measurements, molecular weight determination and SEM analysis  
35 of hydrogel microstructure. Osteogenic differentiation of encapsulated MSCs was confirmed  
36 by osteogenic Runx2, collagen type I and osteocalcin immunostaining and alkaline  
37 phosphatase quantification. The deposition of late osteogenic markers (calcium phosphates)  
38 detected by Alizarin red and von Kossa staining indicated an extracellular matrix  
39 mineralization.

40

41

42

43

44

45

46 **Keywords:** chitosan; differentiation; hydrogel; hydroxyapatite; MSCs; osteogenesis

47

48

49

## 50 **1. Introduction**

51 Over the past decade, injectable hydrogels have emerged as promising biomaterials for  
52 tissue engineering applications since they are generally biocompatible, biodegradable and can  
53 mimic the extracellular matrix (ECM) architecture. With the fast development of cell-based  
54 therapies, there is a growing need to develop injectable hydrogels as cell carriers, potentially  
55 avoiding an open surgery procedure and facilitating the use of minimally invasive approaches  
56 for material and cell delivery. The hydrogel precursor loaded with cells can be injected into  
57 the wound site, and experiences a sol–gel transition *in situ* due to physical or chemical  
58 stimuli.

59 In the past years, many chitosan (Cht) based hydrogels have been developed for  
60 biomedical applications, as it is well documented and analyzed in review papers (Liu et al.,  
61 2017; Racine, Texier & Auzély-Velty, 2017; Ta, Dass & Dunstan, 2008). A particular focus  
62 has been on chitosan hydrogels based on thermosensitive sol–gel transition initiated by  
63 glycerophosphate salt at body temperature, invented by Chenite et al. (Chenite, Buschmann,  
64 Wang, Chaput, & Kandani, 2001). The ability of chitosan-based hydrogels to support  
65 chondrogenic differentiation of human mesenchymal stem cells (hMSCs) has been confirmed  
66 (Cho et al., 2004; Dang et al., 2006). By combining chitosan–glycerophosphate with different  
67 concentrations of starch, a thermoresponsive hydrogel, that can be used as an injectable  
68 vehicle for cell delivery, has been prepared (Sa-Lima, Caridade, Mano, & Reis, 2010).  
69 Naderi-Meshkin et al. (Naderi-Meshkin et al., 2014) have developed a chitosan based  
70 injectable hydrogel via the combination of chitosan, glycerol phosphate, and hydroxyethyl  
71 cellulose. Systematic investigations of the viability, proliferation, and differentiation capacity  
72 of encapsulated mesenchymal stem cells in the hydrogel have indicated that the hydrogel has  
73 a high potential for cartilage tissue engineering. The study with human adipose-derived stem  
74 cells grown on chitosan hydrogel, cross-linked by 0.5% glutaraldehyde, (Debnath et al., 2015)

75 has revealed that chitosan hydrogel promotes cell proliferation coupled with > 90% cell  
76 viability.

77 Chitosan hydrogels loaded with inorganic particles, such as hydroxyapatite (HAp),  
78 which is the inorganic component of bone and constitutes 60 % of native bone ECM, have  
79 been prepared to improve mechanical properties and bioactivity of hydrogels. The addition of  
80 hydroxyapatite phase into chitosan-based material has indicated better cell and protein  
81 adhesion, enhanced cell proliferation and higher osteogenic gene expression (Frohbergh et al.,  
82 2012; Peter et al., 2010). Moreover, stem cell culture on chitosan-hydroxyapatite scaffolds  
83 modified by growth factors has been proposed as good strategy for bone tissue reconstruction  
84 (Liu et al., 2013). In a recent study (Demirtas, Irmak & Gümüşderelioğlu, 2017) a chitosan  
85 solution and its composite with nanostructured hydroxyapatite were mixed with cells and  
86 bioprinted successfully. It was observed that MC3T3-E1 pre-osteoblast cells within chitosan  
87 and chitosan-HA hydrogels had mineralized and differentiated osteogenically after 21 days of  
88 culture. It was proven that the presence of hydroxyapatite in chitosan hydrogels improved cell  
89 viability, proliferation and osteogenic differentiation.

90

91 In our recent study (Rogina et al., 2017b) a novel pH-responsive chitosan-  
92 hydroxyapatite hydrogel, physically crosslinked with sodium bicarbonate, that allowed non-  
93 cytotoxic fast gelation within 4 min, was prepared, with 30% (w/w) of HAp phase. The *in situ*  
94 synthesis of apatite phase has facilitated the physical crosslinking by reducing the acidity of  
95 the chitosan solution. Preliminary biological characterization of the hydrogel, performed by  
96 MTT test and live-dead assay, indicated good distribution and viability of encapsulated mouse  
97 embryonic fibroblasts and good resistance to shear. Based on these results we hypothesized  
98 that proposed injectable hydrogel could be a suitable osteoconductive cellular carrier.

99            *In this work, as a continuation of previous studies, in vitro enzymatic degradation of*  
100 *the hydrogel, during 28 days of incubation, in simulated physiological condiditons, has been*  
101 *analyzed. To evaluate the osteogenic potential of the hydrogel, an extensive biological*  
102 *characterization has been preformed as well, using porcine mesenchymal stem cells. Since our*  
103 *recent studies proved the osteogenic potential of highly porous composite Cht/HAp scaffold,*  
104 *with 30 wt% of in situ formed HAp, prepared by precipitation reaction and freeze-gelation*  
105 *method in static and dynamic cell culture conditions (Rogina et al., 2016; Rogina et al.,*  
106 *2017a) in this work, we used the Cht/HAp scaffold, as a control. We hypothesized that the*  
107 *cellular response to chemically identical biomaterials may depend on the way the cells were*  
108 *incorporated in biomaterial. Therefore, two methods were applied: (1) MSCs were*  
109 *encapsulated during chitosan-hydroxyapatite hydrogel formation and (2) cells were seeded*  
110 *onto prefabricated porous chitosan-hydroxyapatite scaffold, and the results of biological*  
111 *characterization were compared.*

112

## 113 **2. Materials and methods**

### 114 2.1. Materials

115            Chitosan (Cht,  $M_w = 100 - 300$  kg/mol, deacetylation degree of 0.95 – 0.98, Acros  
116 Organics; sterilised with 96% of ethanol), calcium carbonate ( $\text{CaCO}_3$ , calcite; TTT; sterilised  
117 by autoclave), urea phosphate ( $(\text{NH}_2)_2\text{CO}-\text{H}_3\text{PO}_4$ ); Aldrich Chemistry; sterilised using 0.22  
118  $\mu\text{m}$  filter), acetic acid (99.5 %, Sigma Aldrich; sterilised using 0.22  $\mu\text{m}$  filter), sodium  
119 bicarbonate ( $\text{NaHCO}_3$ , Gram-Mol; sterilised using 0.22  $\mu\text{m}$  filter), sodium hydroxide (NaOH,  
120 Gram-Mol) and ethanol (EtOH, 96% Kefo) were all of analytical grade. Lysozyme (from hen  
121 egg white,  $\geq 54\ 000$  U/mg protein) in the form of powder was purchased from Sigma-Aldrich.

122

## 123 2.2. Synthesis of pH-responsive Cht/HAp hydrogel and scaffold

124

125 Based on our previous study (Rogina et al., 2015) chitosan-hydroxyapatite suspension  
126 was prepared by *in situ* wet precipitation method. Briefly, 1.2 wt% of chitosan (Cht) solution  
127 was prepared in 0.36 wt% acetic acid (HAc). Then, calcite ( $\text{CaCO}_3$ ) and urea phosphate  
128 ( $(\text{NH}_2)_2\text{CO}-\text{H}_3\text{PO}_4$ ) were added into Cht solution with Ca/P ratio of 1.67 to obtain 30 wt% of  
129 hydroxyapatite in final composite. This HAp content was selected based on our previous  
130 studies on chitosan composite scaffolds (Rogina et al., 2015; Rogina et al., 2016; Rogina et  
131 al., 2017a) where it resulted optimal in terms of mechanical and biological response as  
132 stimulates osteogenesis.

133 The mixture was stirred 4 days at 50 °C. After 4 days of reaction, the Cht/HAp suspension  
134 was cooled down naturally to ambient temperature and used for preparation of pH-responsive  
135 hydrogel (1) and control material (2).

136 (1) The pH-responsive, Cht/HAp system was prepared using 0.067 mg/L solution of sodium  
137 bicarbonate prepared in basal  $\alpha$ -MEM (minimum essential medium), as described previously  
138 (Rogina et al., 2017b). After cooling down the Cht/HAp suspension and  $\text{NaHCO}_3/\alpha$ -MEM  
139 solution to 10 °C using ice bath, components were mixed together for 10 sec by stirring at  
140 1700 rpm. Homogenized suspension was then incubated at 37 °C to initiate physical  
141 crosslinking of Cht/HAp hydrogel.

142 (2) The Cht/HAp scaffolds prepared by thermally induced phase separation and extraction  
143 (Rogina et al., 2015) were used as control materials. Briefly, Cht/HAp suspension was frozen  
144 over night at -22 °C and immersed in NaOH/EtOH (1:1 of volume portion) solution for 12 h  
145 at -22 °C. Then, samples were immersed in ethanol for 12 h at -22 °C and finally dehydrated  
146 in ethanol for 24 h, at ambient temperature.

## 147 2.3. *In vitro* enzymatic degradation

148 The degradation behaviour of Cht/HAp crosslinked hydrogel was studied at two  
149 different concentrations of lysozyme (1.5 µg/mL corresponding to an activity of 82 U/mL and  
150 500 µg/mL corresponding to an activity of 27 300 U/mL) under static physiological  
151 conditions (phosphate buffer saline solution, PBS) on five replicas. Crosslinked hydrogels ( $n$   
152 = 5, 500 µL) were incubated in 5 mL of PBS containing lysozyme at 37 °C during 28 days.  
153 Freshly prepared degradation medium was changed every third day to maintain the activity of  
154 lysozyme and to mimic physiological conditions *in vivo* (Porstmann et al., 1989). The  
155 Cht/HAp hydrogels were also incubated in phosphate buffer saline solution without  
156 containing lysozyme. At defined time points, the degradation medium was carefully removed  
157 in order to determine the weight of swollen hydrogel samples ( $W_s$ ). Then, samples were  
158 lyophilised ( $W_d$ ) and swelling ratio was calculated according to equation 1:

159

$$160 \text{ Swelling ratio}(\%) = \frac{W_s - W_d}{W_d} \times 100 \quad (1)$$

161

162 The degradation of hydrogels was determined as the ratio of remaining hydrogel weight ( $W_d$ )  
163 and initial weight of the sample ( $W_{d0}$ ) before enzymatic degradation (Eq. 2).

164

$$165 \text{ Dry weight remaining ratio}(\%) = \frac{W_d}{W_{d0}} \times 100 \quad (2)$$

166

167 The influence of degradation medium on hydrogels' microstructure was analysed by scanning  
168 electron microscopy (SEM). Dried degraded samples were coated with plasma of gold and  
169 palladium for 90 s. The microscopic imaging was carried out by the electron microscope  
170 TESCAN Vega3SEM Easyprobe at electron beam energy of 15 keV.

171



## 172 2.4. Gel permeation chromatography

173 The distribution of molecular weight of Cht/HAp hydrogels during enzymatic  
174 degradation was analysed by Gel Permeation Chromatography (GPC), at 35 °C, with a Waters  
175 Breeze GPC system and a 1525 Binary HPLC pump (Waters Corporation, Milford, MA)  
176 equipped with a 2414 refractive index detector and four serial columns of water  
177 (Ultrahydrogel 7.8 mm ID X 30 cm). The degraded hydrogel samples were dissolved in acetic  
178 buffer (CH<sub>3</sub>COOH 0.5 M/CH<sub>3</sub>COONa 0.2 M, pH = 4.5) used as a mobile phase at a flow rate  
179 of 0.5 mL/min and 20 µL injection volume, as previously described by Gámiz-González et al.  
180 (Gámiz-González et al., 2015).

181

## 182 2.5. Cell encapsulation/seedling

183 Porcine mesenchymal stem cells from bone marrow were obtained, using a modified protocol  
184 for human MSCs isolation (Gamiz-Gonzalez et al., 2017; Lennon & Caplan, 2006; Rodenas-  
185 Rochina, Kelly, Ribelles & Lebourg, 2016; Thorpe et al., 2008). For expansion, the cells were  
186 seeded at  $4 \times 10^5$  cells/cm<sup>2</sup> in a T75 cm<sup>2</sup> culture flask with high glucose Dulbecco's modified  
187 Eagle's medium (DMEM), enriched with 10% of FBS, 2% penicillin/streptomycin and 125  
188 µg/mL amphotericin B until passage 1. From passage 1 to 3 culture media was supplemented  
189 with 5 ng/mL recombinant human fibroblast growth factor- 2 and without amphotericin B.  
190 Cells at passage 3 were used for tri-potentiality assessment (Thorpe et al., 2008) and cell  
191 culture seeding.

192 For cell encapsulation, the cells were resuspended at a density of  $1.4 \times 10^6$  cells/mL in a  
193 Cht/HAp/NaHCO<sub>3</sub> solution, with pH of 7.01 and at 10 °C suitable for cell survival, as  
194 described in our previous study (Rogina, et al.; 2017b).

195 The cell/hydrogel system was quickly seeded on 24-well plates, 200  $\mu\text{L}$  per well, and  
196 incubated in humidified atmosphere at 37 °C and 5% of  $\text{CO}_2$  for 4 min to induce physical  
197 crosslinking. Then, samples were incubated with 2 mL of DMEM medium supplemented with  
198 10% of FBS (fetal bovine serum) and 1% of penicillin/streptomycin in a humidified  
199 atmosphere with 5%  $\text{CO}_2$  at 37 °C for 24 h. After 24 h, basal medium was changed with  
200 DMEM supplemented with 10% of FBS, 1% of penicillin/streptomycin, 50  $\mu\text{g}/\text{mL}$  of ascorbic  
201 acid, 10 mmol/L of  $\beta$ -glycerophosphate and 1  $\mu\text{mol}/\text{L}$  of dexamethasone. The medium was  
202 refreshed every third day.

203 As a control material, Cht/HAp scaffolds were cut into cylindrical shape pieces of 7 mm  
204 diameter and 1-2 mm height, sterilized in 96% ethanol and conserved at 4 °C for 24 h. After  
205 sterilization, scaffolds were washed 3 times with Dulbecco's modified Eagle's culture  
206 medium (DMEM), left in DMEM for 24 h and transported into 24-well plate. Scaffolds were  
207 seeded with the same cell density as hydrogels, according to the volume of the scaffold. The  
208 cells suspension was put on top of the scaffold and incubated for 15 min to allow cells  
209 attachment and migration inside the scaffold. Then cell culture media was added in the same  
210 way as for the hydrogels.

211

## 212 2.6. Cell Counting

213 Cell proliferation into Cht/HAp hydrogels and control materials was examined at 1, 7  
214 and 14 days of culture. After cutting three 50  $\mu\text{m}$  slices, of five different replicas, samples  
215 were stained with DAPI. Images were taken by confocal fluorescence microscope (Zeiss LSM  
216 780, Axio Observer) in 16-tile mode scanning and the cell nuclei were counted. Average  
217 number of cells at different time points is expressed as average value corrected by standard  
218 error of the mean (SEM).

219

## 220 2.7. Alkaline phosphatase analysis

221 The activity of alkaline phosphatase (ALP) was measured as the conversion of p-  
222 nitrophenylphosphate to p-nitrophenol as the result of the cellular extract activity, using  
223 SensoLyte® pNPP Alkaline Phosphatase Assay kit \*Colorimetric\* (AnaSpec) according to  
224 the manufacturer instructions. Samples were gathered at 7 and 14 days. For each time point,  
225 three acellular samples were used as blanks. After washing the samples with Dulbecco's  
226 phosphate buffered saline (DPBS) and lysis buffer (DPBS 1X with 0.2 % Triton X-100)  
227 solution, 200 µL of lysis buffer was added and homogenized with hydrogel. All samples were  
228 incubated in ice bath and centrifuged at 4 °C for 7 min to precipitate cellular and material  
229 debris. Then, 50 µL of each standard and sample with 50 µL of p-nitrophenylphosphate were  
230 placed in 96-well plate in triplicates. The plate was incubated in the dark for 40 min at room  
231 temperature. Absorbance was measured at 405 nm using Perkin-Elmer VICTOR3 multi-plate  
232 reader. The concentration of the ALP was determined using a standard curve.

## 233 2.8. Immunofluorescent imaging of cell markers

234 Differentiation of MSCs at 7 and 14 days was evaluated by different antibodies to  
235 confirm the expression of differentiation markers: runt-related transcription factor 2 (Runx2),  
236 collagen type I (COLL I) and osteocalcin (OCN). Cultured samples were fixed in 4% of  
237 formaldehyde at 4 °C for 1 h and washed with DPBS. Sample slices of Cht/HAp hydrogels  
238 with 50 µm of thickness were permeabilized with DPBS/0.5% Triton X-100 for 5 min at room  
239 temperature, further treated with 1% of sodium dodecyl sulfate (SDS) in DPBS for 5 minutes  
240 to perform the antigen retrieval, and subsequently washed with DPBS. Then, samples were  
241 blocked by DPBS/1% bovine serum albumin (BSA)/10% goat serum for 30 min. Incubation  
242 with primary antibodies, with dilution 1:50 (Runx2), 1:100, (COLL I) and 1:200 (OCN) in

243 DPBS/ 1% bovine serum BSA /10% goat serum, was performed for 5 h at room temperature.  
244 Further, samples were washed with DPBS/0.05% Tween 20 surfactant and incubated with  
245 Bodipy FL Dye (Fisher) dilution 1:400 to stain the cytoskeleton and secondary antibody anti-  
246 mouse conjugated with alexa 555 for 1 h at room temperature. Incubation with secondary  
247 antibodies was not performed for Runx2, because primary antibody is labelled FITC. Finally,  
248 samples were mounted with Vectashield DAPI for nuclei staining. Detection of protein  
249 markers was performed by confocal fluorescence microscope (Zeiss LSM 780, Axio  
250 Observer).

251 The staining antibodies on control materials were performed on whole sample. After washing  
252 second antibodies, control materials were fixed and included in cryoprotective medium at -80  
253 °C. Then, samples were cut into slices with 50 µm of thickness and mounted with Vectashield  
254 DAPI.

## 255 2.9. Histological Analysis

256 Cultured samples were fixed with formaldehyde, included in optimum cutting  
257 temperature compound (OCT), frozen at -80 °C and cut into slices with 17 µm of thickness.  
258 Detection of phosphate deposits on Cht/HAp hydrogels were determined using von Kossa  
259 staining. Samples were washed with distilled water and incubated in a 5% AgNO<sub>3</sub> solution  
260 (Sigma-Aldrich) under ultraviolet light for 20 min. Further, samples were washed with  
261 distilled water and 2% Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (Sigma-Aldrich) to remove unreacted AgNO<sub>3</sub>. Finally, the  
262 cells were stained using a neutral red solution (Sigma-Aldrich) for 2 minutes. Detection of  
263 calcium deposits was determined using Alizarin red S staining. Samples were incubated with  
264 2% of alizarin red solution (pH of 4.2; Sigma-Aldrich) for 4 minutes. After staining, samples  
265 were washed with distilled water and mounted with 80% of glycerol solution (Sigma-  
266 Aldrich).

## 267 2.10. Statistical analysis

268 All experiments were performed in triplicates or more. Statistical comparison between  
269 two groups was tested using one-way ANOVA test with value  $p < 0.05$  and  $p < 0.01$   
270 considered statistically significant.

271

## 272 3. Results


### 273 3.1. *In vitro* degradation testing

274 In the present study, enzymatic degradation of Cht/HAp hydrogel was studied at 37 °C  
275 as a function of time, for 28 days, by monitoring swelling behaviour, dry weight loss,  
276 molecular weight ( $M_w$ ) and polydispersity index ( $PDI$ ). To distinguish between enzymatic  
277 degradation and dissolution, Cht/HAp hydrogels were exposed to phosphate buffer solution  
278 (PBS) without and with (1.5 and 500 µg/mL) lysozyme, as used in reported studies (Jin et al.,  
279 2009; Moura, Faneca, Lima, Gil & Figueiredo, 2011; Yang et al., 2010). The lysozyme  
280 concentration of 500 µg/mL better mimics the *in vivo* physiological conditions, as the  
281 lysozyme level in the extracellular matrix of human tissues can increase up to 1,000- fold  
282 (Hou et al., 2012) the amount usually found in serum (0.95~2.45 µg/mL) (Jin et al., 2009;  
283 Park, Choi & Lee, 2013;).

284 The results shown in Fig. 1a suggest an increase in swelling ratio with incubation time for all  
285 investigated systems. However, there is no significant difference in swelling ratios among 3,  
286 14 and 28 days for Cht/HAp hydrogels (Fig. 1a) incubated in non-enzymatic conditions  
287 (Cht/HAp\_PBS) and in 1.5 µg/mL of lysozyme solution (Cht/HAp\_1.5 µg/mL). For Cht/HAp  
288 hydrogel incubated in the 500 µg/mL of lysozyme solution (Cht/HAp\_500µg/mL) there is a  
289 significant difference between swelling ratios between 3 and 28 days. As seen from Figure 1b  
290 the weight loss of Cht/HAp hydrogel in different incubation media follows the decreasing

291 trend: PBS < 1.5  $\mu\text{g/mL}$  of lysozyme solution < 500  $\mu\text{g/mL}$  of lysozyme solution. However,  
292 there is no significant difference in dry weight remaining ratio among 3, 14 and 28 days.  
293 Weight average molecular weight ( $M_w$ ) reduction during incubation was observed in all  
294 investigated systems (Fig. 1c), and the degradation is the most pronounced in 500  $\mu\text{g/mL}$  of  
295 lysozyme solution. Initial molecular weight,  $M_{w0} \approx 222\ 000$ , decreased after 3 and 28 days, in  
296 non-enzymatic condition to 170 000 and 113 000, respectively, in 1.5  $\mu\text{g/mL}$  of lysozyme  
297 solution to 123 000 and 79 000, respectively, and in 500  $\mu\text{g/mL}$  of lysozyme solution to 48  
298 000 and 36 500, respectively. Polydispersity index stayed around 2 throughout all degradation  
299 process which could indicate a random depolymerisation (Holme, Davidsen, Kristiansen &  
300 Smidsrød, 2008).

301 In all investigated systems the decrease in molecular weight is accompanied by an increase of  
302 the swelling ratio, but only in system Cht/HAp\_500 $\mu\text{g/mL}$  a significant difference in swelling  
303 ratio between 3 and 28 days was observed. It is expected that shorter chitosan chains in  
304 Cht/HAp\_500 $\mu\text{g/mL}$ , show smaller extent of chain entanglements and physical crosslinking  
305 density, compared to other two investigated systems, resulting in higher swelling ratios. To  
306 provide a better understanding of the correlation between chitosan molecular weight and  
307 swelling ratio other molecular parameters that describe the network structure of hydrogels  
308 should be determined, such as the critical entanglement molecular weight and the average  
309 molecular weight between crosslinks. (i.e., mesh size).




310

311 Fig. 1. Swelling ratio (a); dry weight remaining ratio (b); and weight average molecular  
 312 weight (c) of Cht/HAp hydrogel incubated in different degradation media at 37 °C as a  
 313 function of time. Significant difference between two groups: \*( $p < 0.05$ ), \*\* ( $p < 0.01$ ).

314 The microstructures of the cross section of Cht/HAp\_PBS and Cht/HAp\_1.5 µg/mL  
 315 hydrogels shown in Fig. 2b confirm larger pores after 3 days of incubation at 37 °C compared  
 316 to initial Cht/HAp hydrogel (0 day), as a result of water absorption. The pore structure of  
 317 Cht/HAp\_500µg/mL hydrogel is fully disrupted after 3 days of incubation as a result of high  
 318 degradation rate. However, it retained the porous structure which is important for the  
 319 diffusion of nutrients, metabolic waste products, and oxygen. In this study, deacetylation  
 320 degree of chitosan is in the range 0.95 – 0.98 and a high stability under enzymatic conditions

321 was expected (Freier, Koh, Kazazian & Shoichet, 2005). After 28 days of incubation highly  
322 porous structure was maintained in all degradation conditions indicating a stable Cht/HAp  
323 hydrogel. SEM micrographs of Cht/HAp hydrogels cross section confirmed uniform  
324 degradation through entire volume of hydrogel and good particles distribution of *in situ*  
325 precipitated HAp within chitosan matrix (see Fig. 2a). In comparison to the hydrogel prepared  
326 by mixing previously prepared hydroxyapatite particles within chitosan/ $\beta$ -glycerophosphate  
327 (Chen et al., 2016) *in situ* precipitation performed in this work results in smaller particles size.

328



329



330 Fig. 2. SEM micrographs of **dried hydrogel with *in situ* precipitated HAp particles within**  
331 **chitosan matrix (a) and Cht/HAp hydrogel incubated for 3 and 28 days under different**  
332 **degradation conditions (b).**


### 333 3.2. Biological characterization

334 As described in experimental section, for both, the hydrogel and the scaffold, **the cell**  
335 **counting was performed by imaging three DAPI stained 50  $\mu\text{m}$  slices, of five different**  
336 **replicas. Images were taken by confocal fluorescence microscope in 16-tile mode scanning.**  
337 **Fig 3a represents the average cell number of the total 16 tiles at 3 different slices. It is**  
338 **noteworthy that counted cell number does not represent total cell number, but average number**  
339 **of cells on material slices imaged in 16-tile mode.**

340 As shown in Fig. 3a, **lower cell number on scaffold at day 0, compared to hydrogel was**  
341 **observed, although, the same number of cells were encapsulated in the hydrogel and seeded**  
342 **on the scaffold. It could indicate that all cells did not succeed to achieve a stable adhesion and**  
343 **could easily detach from the scaffold.** An increase in the number of cells after 7 days of  
344 culture was obtained in both Cht/HAp hydrogel and the control, indicating that new injectable  
345 Cht/HAp hydrogel is suitable for cell encapsulation and proliferation and can be used as a cell  
346 carrier for bone tissue engineering. After an initial increase in cell number, there is not a  
347 significant difference in the average cell number between 7 and 14 days. This could indicate  
348 that cells stopped proliferating and probably started to differentiate, what was confirmed by  
349 the presence of osteogenic markers, as will be shown below. Figure S1 of Supplementary  
350 material confirms that cells stayed homogeneously dispersed inside hydrogel during 14 days  
351 of cell culture indicating that the microstructure and physically crosslinked chitosan chains do  
352 not allow cell to migrate outside the hydrogel.

353


354 Cells secrete alkaline phosphatase, a characteristic parameter of osteoblasts. Although  
355 there is no significant difference in ALP concentration (Fig. 3b) between 7 and 14 days of cell  
356 culture in the Cht/HAp hydrogel, it seems that the tendency is to increase with the culture  
357 time. A clear significant increase of ALP secretion was measured in the control scaffolds.



358  
359 Fig. 3. The cell number (a) and alkaline phosphatase activity (ALP) (b) of MSCs encapsulated  
360 in Cht/HAp hydrogel and control after 7 and 14 days of cell culture. Significant difference  
361 between two groups ( $p < 0.05$ ) is designated with (\*).

362 Along with ALP activity quantification, osteogenic differentiation of MSC cells  
363 encapsulated in Cht/HAp hydrogel was determined by analysing the expression of runt-related  
364 transcription factor 2 (Runx2), collagen I (COLL I) and osteocalcin (OCN) at 7 and 14 days  
365 of cell culture. Images obtained by confocal fluorescence microscopy are shown in Fig. 4a-c.  
366 Cell nuclei stained with DAPI appeared in blue, while Runx2 (Fig. 4a) appeared in green,  
367 COLL I (Fig. 4b) and OCN (Fig. 4c) appeared in red and cytoskeleton (actin) in green.  
368 Unfortunately, the quality of immunofluorescence images is poor due to strong auto-  
369 fluorescence of hydrogel/scaffold. To minimize the sample interference the images were  
370 processed by ImageJ software, which resulted in darkening of the final image. To compensate  
371 this we completed the study with additional colorimetric stains (alizarin red and von Kossa) as  
372 will be shown later.

373 Previous *in vitro* studies (Komori, 2003) demonstrated that Runx2 can enhance the expression  
374 of bone matrix genes like collagen type I, osteopontin, osteocalcin, bone sialoprotein (BSP)  
375 and fibronectin. According to that, expression of COLL I and OCN was expected and found at  
376 7 and 14 days of cell culture, implying good osteogenic potential of prepared Cht/HAp  
377 hydrogel. The round shape morphology of MSCs is evident after 7 and 14 days of cell culture,  
378 which is consistent with the literature (Wang, Rao & Stegemann, 2013; Caliri, Vega, Kwon,  
379 Soulas & Burdick, 2016).




380

381 Fig. 4. The expression of Runx2 (a), collagen type I (COLL I) (b) and osteocalcin (OCN) (c)  
 382 encapsulated in Cht/HAp hydrogels after 7 and 14 days of cell culture. Cell nucleus stained  
 383 with Dapi (blue fluorescence), Runx2 (green fluorescence) (a). Actin cytoskeleton stained

384 with phalloidin (green fluorescence), COLL I and OCN (red fluorescence) (b and c). Scale  
385 bar: 50  $\mu\text{m}$ .

386 Mineralized ECM in the Cht/HAp hydrogels was identified by von Kossa and Alizarin  
387 red staining (Fig. 5), where calcium deposits are positively stained in red and phosphate  
388 deposits in brown or black. After 7 and 14 days of culture higher intensity of red and brown  
389 (black) deposits indicate that mineralization of ECM occurred. Obtained results of  
390 differentiated cells after 7 and 14 days of cell culture were compared with Cht/HAp hydrogel  
391 with undifferentiated cells at day 0 (Ctrl in Fig. 5).



392

393 Fig. 5. Positive staining for calcium deposits after 7 and 14 days of culture is observable by  
394 red colour determined using alizarin red S assay. Positive staining for phosphate deposits after  
395 7 and 14 days is observable by brown and black colour determined using von Kossa assay.  
396 Cht/HAp hydrogel with undifferentiated cells was used to indicate the material/cell  
397 interference (Ctrl). Scale bar: 100  $\mu\text{m}$ .

#### 398 4. Discussion

399 In our previous study (Rogina et al., 2017b) an injectable, pH-responsive, physically  
400 crosslinked hydrogel based on chitosan and *in situ* formed hydroxyapatite, with 30% (w/w) of  
401 HAp phase, was prepared. The viscoelastic behaviour of hydrogel was observed in the range  
402 of strain deformation up to approximately 10%. The  $G''/G'$  ratio of 0.04 and linear  
403 viscoelasticity above 5% of strain deformation, indicated that chitosan/HAp hydrogel could  
404 behave as a strong physical gel. Compared to the storage modulus of similar physically  
405 crosslinked chitosan-based system, with 30% (w/w) of bioglass nanoparticles, and  $\beta$ -  
406 glycerophosphate as a gelling agent (Couto, Hong & Mano, 2009) our gel showed 1.5-fold  
407 higher storage modulus, indicating better resistance to shear. Distribution and viability of  
408 encapsulated mouse embryonic fibroblasts within the hydrogel up to 7 days of culture was  
409 confirmed by *live dead* staining.

410 As a continuation of previous study, in this work an extensive *in vitro* characterization of the  
411 hydrogel, using porcine MSCs, was performed, including, *in vitro* enzymatic degradation  
412 during 28 days of incubation, in simulated physiological conditions. It was hypothesized that  
413 *in situ* synthesis of hydroxyapatite within chitosan matrix would provide a homogeneous  
414 dispersion of hydroxyapatite particles with positive influence on osteoinduction and  
415 differentiation of MSCs that can lead to homogeneous bone regeneration.

416 Swelling behaviour, structural integrity and rate of degradation are critical variables in  
417 hydrogel design that affect the rate of tissue formation. Hydrogels derived from natural  
418 polymers often are not stable at physiological conditions and undergo rapid degradation (Tan  
419 & Marra, 2010). As cell carriers, hydrogels stability during cell encapsulation and  
420 differentiation at physiological conditions is required. Chitosan has the ability to readily swell  
421 up when exposed in a biological environment. Degradation of chitosan takes place via  
422 hydrolysis, as interactions with water molecules break the polymeric network into smaller  
423 chains whereby the  $\beta$ -1-4 N-acetyl glucosamine units of Cht undergo chain scission mainly by

424 lysozymes present in the body. This phenomenon leads to release of amino sugars, which can  
425 be incorporated into metabolic pathways or excreted through the body (Liu, Zhou & Sun,  
426 2012; Qasim et al., 2017; Ren, Yi, Wang & Ma, 2005; Tomihata & Ikada, 1997). Other by  
427 products of Cht degradation include saccharides which become part of the normal metabolic  
428 process (Kumar, Muzzarelli, Muzzarelli, Sashiwa & Domb, 2004).

429 The results obtained in this work show that new physically crosslinked Cht/HAp hydrogel is  
430 highly stable during 28 days, even in extreme conditions with much higher concentration of  
431 lysozyme than physiological, which is important for the eventual future clinical application of  
432 the material. The weight loss after 28 days of incubation is comparable to the literature data  
433 reported for chemically crosslinked hydrogels based on chitosan, showing 30 – 70 % weight  
434 loss after 28 days of incubation under enzymatic physiological conditions, depending on  
435 crosslinking degree (Moura et al., 2011; Xu et al., 2016). The big advantage of the synthesis  
436 applied in present work is simple chitosan gel formation, feasible under mild conditions,  
437 without using toxic cross-linking agents. The cross-sectional SEM images of the freeze-dried  
438 hydrogels (Fig. 2) demonstrate a porous and netlike structure and good particles distribution  
439 of *in situ* precipitated HAp within chitosan matrix. The porous structures provide an  
440 environment suitable for the attachment, growth, and differentiation of MSCs, and transport  
441 of nutrients to the cells.

442 Many *in vitro* and *in vivo* studies have suggested that MSCs have the potential to enhance  
443 osteogenesis while being delivered in critical sized bone defects with ability to migrate to  
444 defect sites. Despite MSCs capacity to differentiate to osteoblasts, MSCs ability to support a  
445 regenerative microenvironment is of great importance. MSCs can differentiate to multiple cell  
446 types like chondrocytes, osteoblasts and adipocytes (Oryan, Kamali, Moshiri & Baghaban  
447 Eslaminejad, 2017). MSCs were encapsulated in an injectable thermosensitive chitosan-  
448 glycerophosphate where differentiation occurred to chondrocytes (Richardson, Hughes, Hunt,

449 Freemont & Hoyland, 2008). The same tendency was observed in other chitosan based  
450 hydrogels (Cho et al., 2004; Jin, 2009; Hu, 2012). Wang and Stegemann (Wang &  
451 Stegemann, 2010) used  $\beta$ -glycerophosphate as gelling agent to obtain physically crosslinked  
452 chitosan hydrogel. High concentration of  $\beta$ -glycerophosphate was required to obtain gelation  
453 time below 10 min. Additionally, DNA content of encapsulated human bone marrow  
454 mesenchymal stem cells decreased over time suggesting that cells were dying in chitosan  
455 hydrogel. Incorporation of previously prepared HAp particles into chitosan/gelatin scaffold  
456 enhanced osteogenic differentiation (Zhao, Grayson, Ma, Bunnell & Lu, 2006). In the present  
457 work the differentiation of MSCs encapsulated in the Cht/HAp hydrogel was evaluated after 7  
458 and 14 days of cell culture. Colorimetric quantification of alkaline phosphatase activity and  
459 immunofluorescent imaging was used to detect the expression of osteogenic markers.

460 Detection of Runx2 as a principal osteogenic master gene for bone formation as well as  
461 COLL I and OCN, characteristic genes of differentiation process, indicates good osteogenic  
462 signal of Cht/HAp hydrogel where MSCs differentiated into an osteoblast phenotype  
463 indicating possible application of Cht/HAp hydrogel as cell carrier for bone tissue  
464 engineering.

465 Osteogenesis depends on the material's composition, surface properties, charge and  
466 wettability, but also on the material stiffness. Literature reports that stiffness of about 1,5 kPa  
467 upregulated osteogenic expression whereas softer matrices are not so osteogenic (Murphy,  
468 Matsiko, Haugh, Gleeson & O'Brien, 2012). That is the possible reason why the injectable  
469 Cht/HAp hydrogel that possess a lower modulus, around 100 Pa (Rogina et.al. 2017b) than  
470 the Cht/HAp scaffold has a lower ALP activity compared to the scaffold.

471 The deposition of late osteogenic markers (calcium phosphates) detected by Alizarin red and  
472 Von Kossa staining indicated an extracellular matrix (ECM) mineralization. It can be



473 concluded that Cht/HAp hydrogel provide suitable environment for enhanced osteogenesis of  
474 MSCs. Further *in vivo* studies on animal model need to be performed to examine  
475 biodegradation and osteogenesis to confirm the applicability of Cht/HAp hydrogel for bone  
476 tissue engineering.

## 477 **5. Conclusion**

478 Present research has shown that novel chitosan/hydroxyapatite physically crosslinked  
479 hydrogel act as the three-dimensional support for MSCs proliferation and differentiation into  
480 osteoblast cells. The expression of characteristic bone genes, Runx2, ALP, COLL I, OCN and  
481 calcium phosphate deposits, indicated that ECM mineralisation took place during 14 days of  
482 cell culture. MSCs are homogeneously dispersed through entire Cht/HAp hydrogel during cell  
483 culture, which is crucial for full bone healing. Prepared Cht/HAp hydrogel is highly stable  
484 under physiological and enzymatic conditions supporting the osteogenesis of encapsulated  
485 mesenchymal stem cells.

## 486 **Acknowledgements**

487 This work has been supported in part by the Croatian Science Foundation under the  
488 project IP-2014-09-3752 by the Spanish Ministry through the MAT2016-76039-C4-1-R  
489 project (including the FEDER financial support). The authors want to thank Laura Teruel  
490 Biosca from Centre for Biomaterials and Tissue Engineering, Universitat Politècnica de  
491 València, for helping with gel permeation chromatography measurements. **Joaquin Ródenas-**  
492 **Rochina acknowledges funding by the Consellería de Educación, Investigación, Cultura y**  
493 **Deporte (Generalitat Valenciana) and co-funding by Fondo Social Europeo (FSE) through**  
494 **APOSTD grant (APOSTD/2016/006).**

## 495 **References**

496 Caliari, S. R., Vega, S. L., Kwon, M., Soulas, E. M., & Burdick, J. A. (2016). Dimensionality  
497 and spreading influence MSC YAP/TAZ signaling in hydrogel environments. *Biomaterials*,  
498 *103*, 314–323.

499 Chen, Y., Zhang, F., Fu, Q., Liu, Y., Wang, Z., & Qi, N. (2016). In vitro proliferation and  
500 osteogenic differentiation of human dental pulp stem cells in injectable thermo-sensitive  
501 chitosan/b-glycerophosphate/hydroxyapatite hydrogel. *Journal of Biomaterials Applications*,  
502 *31*, 317–327.

503 Chenite, A., Buschmann, M., Wang, D., Chaput, C., & Kandani, N. (2001). Rheological  
504 characterisation of thermogelling chitosan/glycerol-phosphate solutions. *Carbohydrate*  
505 *Polymers*, *46*, 39–47.

506 Cho, J. H., Kim, S. H., Park, K. D., Jung, M. C., Yang, W. I., Han, S. W., Noh, J. Y., & Lee,  
507 J. W. (2004). Chondrogenic differentiation of human mesenchymal stem cells using a  
508 thermosensitive poly(N-isopropylacrylamide) and water-soluble chitosan copolymer.  
509 *Biomaterials*, *25*, 5743–5751.

510 Couto, D. S., Hong, Z., & Mano, J. F. (2009). Development of bioactive and biodegradable  
511 chitosan-based injectable systems containing bioactive glass nanoparticles. *Acta*  
512 *Biomaterialia*, *5*, 115–123.

513 Dang, J. M., Sun, D. D., Shin-Ya, Y., Sieber, A. N., Kostuik, J. P., & Leong, K. W. (2006).  
514 Temperature-responsive hydroxybutyl chitosan for the culture of mesenchymal stem cells and  
515 intervertebral disk cells. *Biomaterials*, *27*, 406–418.

516 Debnath, T., Ghosh, S., Potlapuvu, U. S., Kona, L., Kamaraju, S. R., Sarkar, S., Gaddam, S.,  
517 & Chelluri, L. K. (2015). Proliferation and Differentiation Potential of Human Adipose-

518 Derived Stem Cells Grown on Chitosan Hydrogel. *PLOS ONE*, 10, Article Number:  
519 e0120803.

520 Demirtaş, T. T., Irmak, G., & Gümüřdereliođlu, M. (2017). A bioprintable form of chitosan  
521 hydrogel for bone tissue engineering. *Biofabrication*, 9, Article number:035003.

522 Freier, T., Koh, H. S., Kazazian, K., & Shoichet, M. S. (2005). Controlling cell adhesion and  
523 degradation of chitosan films by N-acetylation. *Biomaterials*, 26, 5872–5878.

524 Frohbergh, M. E., Katsman, A., Botta, G. P., Lazarovici, P., Schauer, C. L., Wegst, U. G. K.,  
525 & Lelkes, P. I. (2012). Electrospun hydroxyapatite-containing chitosan nanofibers crosslinked  
526 with genipin for bone tissue engineering. *Biomaterials*, 33, 9167–9178.

527 Gámiz-González, M. A., Guldris, P., Antolinos Turpín, C. M., Ródenas Rochina, J., Vidaurre,  
528 A., & Gómez Ribelles, J. L. (2017). Fast degrading polymer networks based on  
529 carboxymethyl chitosan, *Materials Today Communications*, 10, 54–66.

530 Holme, H. K., Davidsen, L., Kristiansen, A., & Smidsrød, O. (2008). Kinetics and  
531 mechanisms of depolymerization of alginate and chitosan in aqueous solution. *Carbohydrate*  
532 *Polymers*, 73, 656–664.

533 Hou, Y. P., Hu, J. L., Park, H., & Lee, M. (2012). Chitosan-based nanoparticles as a sustained  
534 protein release carrier for tissue engineering applications. *Journal of Biomedical Materials*  
535 *Research A*, 100, 939–944.

536 Hu, J., Hou, Y., Park, H., Choi, B., Hou, S., Chung, A., & Lee, M. (2012). Visible light  
537 crosslinkable chitosan hydrogels for tissue engineering. *Acta Biomaterialia*, 8, 1730–1738.

538 Jin, R., Moreira Teixeira, L. S., Dijkstra, P. J., Karperien, M., van Blitterswijk, C. A., Zhong,  
539 Z. Y., & Feijen, J. (2009). Injectable chitosan-based hydrogels for cartilage tissue  
540 engineering. *Biomaterials*, 30, 2544–2551.

541 Komori, T. (2003). Requisite roles of Runx2 and Cbfb in skeletal development. *Journal of*  
542 *Bone and Mineral Metabolism*, 21, 193–197.

543 Kumar, M. N. V. R., Muzzarelli, R. A. A., Muzzarelli, C., Sashiwa, H., & Domb, A. J.  
544 (2004). Chitosan chemistry and pharmaceutical perspectives. *Chemical Reviews*, 104, 6017–  
545 6084.

546 Lennon, D. P., & Caplan Al. (2006). Isolation of human marrow-derived mesenchymal stem  
547 cells. *Experimental Hematology*, 34, 1604–1605.

548 Liu, H., Peng, H., Wu, Y., Zhang, C., Cai, Y., Xu, G., Li, Q., Chen, X., Ji, J., Zhang, Y.,  
549 OuYang, H. W. (2013). The promotion of bone regeneration by nanofibrous  
550 hydroxyapatite/chitosan scaffolds by effects on integrin-BMP/Smad signaling pathway in  
551 BMSCs. *Biomaterials*, 34, 4404–4417.

552 Liu, M., Zeng, X., Ma, C., Yi., H., Ali, Z., Mou, X., Li, S., Deng, Y., & He, N. (2017).  
553 Injectable hydrogels for cartilage and bone tissue engineering. *Bone Research*, 5, Article  
554 Number: 17014.

555 Liu, Y., Zhou, C., & Sun, Y. (2012). A biomimetic strategy for controllable degradation of  
556 chitosan scaffolds. *Journal of Materials Research*, 27, 1859–1868.

557 Moura, M. J., Faneca, H., Lima, M .P., Gil, M. H., & Figueiredo, M. M. (2011). In Situ  
558 Forming Chitosan Hydrogels Prepared via Ionic/Covalent Co-Cross-Linking.  
559 *Biomacromolecules*, 12, 3275–3284.

560 Murphy, C. M., Matsiko, A., Haugh, M. G., Gleeson, J. P., & O'Brien, F. J. (2012).  
561 Mesenchymal stem cell fate is regulated by the composition and mechanical properties of  
562 collagen-glycosaminoglycan scaffolds. *Journal of the Mechanical Behavior of Biomedical*  
563 *Materials*, 11, 53–62.

564 Naderi-Meshkin, H., Andreas, K., Matin, M. M., Sittinger, M., Bidkhor, H. R., Ahmadiankia,  
565 N., Bahrami, A. R., & Ringe, J. (2014). Chitosan-based injectable hydrogel as a promising in  
566 situ forming scaffold for cartilage tissue engineering. *Cell Biology International*, 38, 72–84.

567 Oryan, A., Kamali, A., Moshiri, A., & Baghaban Eslaminejad, M. (2017). Role of  
568 Mesenchymal Stem Cells in Bone Regenerative Medicine: What Is the Evidence?. *Cells*  
569 *Tissues Organs*, 204, 59–83.

570 Park, H., Choi, B., Hu, J., & Lee, M. (2013). Injectable chitosan hyaluronic acid hydrogels for  
571 cartilage tissue engineering. *Acta Biomaterialia*, 9, 4779–4786.

572 Peter, M., Ganesh, N., Selvamurugan, N., Nair, S. V., Furuike, T., Tamura, H., & Jayakumar,  
573 R. (2010). Preparation and characterization of chitosan-gelatin/nanohydroxyapatite composite  
574 scaffolds for tissue engineering applications. *Carbohydrate Polymers*, 80, 687–694.

575 Porstmann, B., Jung, K., Schmechta, H., Evers, U., Pergande, M., Porstmann, T., Kramm, H.  
576 J., & Krause, H. (1989). Measurement of lysozyme in human body fluids: comparison of  
577 various enzyme immunoassay techniques and their diagnostic application. *Clinical*  
578 *Biochemistry*, 22, 349–355.

579 Qasim, S. B., Husain, S., Huang, Y., Pogorielov, M., Deineka, V., Lyndin, M, Rawlinson, A.,  
580 & Rahman, I. U. (2017). In-vitro and in-vivo degradation studies of freeze gelated porous  
581 chitosan composite scaffolds for tissue engineering applications. *Polymer Degradation and*  
582 *Stability*, 136, 31–38.

583 Racine L., Texier, I., & Auzély-Velty, R. (2017). Chitosan-based hydrogels: recent design  
584 concepts to tailor properties and functions. *Polymer International*, 66, 981–998.

585 Ren, D., Yi, H., Wang, W., & Ma, X. (2005). The enzymatic degradation and swelling  
586 properties of chitosan matrices with different degrees of N-acetylation. *Carbohydrate*  
587 *research*, 340, 2403–2410.

588 Richardson, S. M., Hughes, N., Hunt, J. A., Freemont, A. J., & Hoyland, J. A. (2008). Human  
589 mesenchymal stem cell differentiation to NP-like cells in chitosan–glycerophosphate  
590 hydrogels. *Biomaterials*, 29, 85–93.

591 Rodenas-Rochina, J., Kelly, D. J., Ribelles, J. L. G., & Lebourg, M. (2016). Compositional  
592 changes to synthetic biodegradable scaffolds modulate the influence of hydrostatic pressure  
593 on chondrogenesis of mesenchymal stem cells. *Biomedical Physics & Engineering Express*, 2,  
594 Article Number: 035005.

595 Rogina, A., Antunović, M., Pribolšan, L., Caput Mihalić, K., Vukasović, A., Ivković, A.,  
596 Marijanović, I., Gallego Ferrer, G., Ivanković, M., & Ivanković, H. (2017a). Human  
597 mesenchymal stem cells differentiation regulated by hydroxyapatite content within chitosan-  
598 based scaffolds under perfusion conditions. *Polymers*, 9, 387–404.

599 Rogina, A., Ressler, A., Matic, I., Gallego Ferrer, G., Marijanović, I., Ivanković, M., &  
600 Ivanković H. (2017b). Cellular hydrogels based on pH-responsive chitosan-hydroxyapatite  
601 system. *Carbohydrate Polymers*, 166, 173–182.

602 Rogina, A., Rico, P., Gallego Ferrer, G., Ivanković, M. & Ivanković, H. (2015). Effect of in  
603 situ formed hydroxyapatite on microstructure of freeze-gelled chitosan-based biocomposite  
604 scaffolds. *European Polymer Journal*, 68, 278–287.

605 Rogina, A., Rico, P., Gallego Ferrer, G., Ivanković, M., & Ivanković, H. (2016). In situ  
606 hydroxyapatite content affects the cell differentiation on porous chitosan/hydroxyapatite  
607 scaffolds. *Annals of Biomedical Engineering*,. 44, 1107–1119.

608 Sá-Lima H., Caridade, S. G., Mano, J. F., & Reis, R. L. (2010). Stimuli-responsive chitosan-  
609 starch injectable hydrogels combined with encapsulated adipose-derived stromal cells for  
610 articular cartilage regeneration. *Soft Matter*, 6, 5184–5195.

611 Ta, H. T., Dass, C. R., & Dunstan, D. E. (2008). Injectable chitosan hydrogels for localised  
612 cancer therapy. *Journal of Controlled Release*, 126, 205–216.

613 Tan, H., & Marra, K. G. (2010). Injectable, biodegradable hydrogels for tissue engineering  
614 applications. *Materials*, 3, 1746–1767.

615 Thorpe, S. D., Buckley, C. T., Vinarfell, T., O'Brien, F. J., Campbell, V. A., & Kelly, D. J.  
616 (2008). Dynamic compression can inhibit chondrogenesis of mesenchymal stem cells.  
617 *Biochemical and Biophysical Research Communications*, 377, 458–462.

618 Tomihata, K., & Ikada, Y. (1997). In vitro and in vivo degradation of films of chitin and its  
619 deacetylated derivatives. *Biomaterials*, 18, 567–575.

620 Wang, L., Rao, R. R., & Stegemann, J. P. (2013). Delivery of Mesenchymal Stem Cells in  
621 Chitosan/Collagen Microbeads for Orthopedic Tissue Repair. *Cells Tissues Organs*, 197,  
622 333–343.

623 Wang, L., & Stegemann, J. P. (2010). Thermogelling chitosan and collagen composite  
624 hydrogels initiated with  $\beta$ -glycerophosphate for bone tissue engineering. *Biomaterials*, 31,  
625 3976–3985.


626 Xu, H., Zhang, L., Bao, Y., Yan, X., Yin, Y., Li, Y., Wang, X., Huang, Z., & Xu, P. (2016).  
627 Preparation and characterization of injectable chitosan–hyaluronic acid hydrogels for nerve  
628 growth factor sustained release. *Journal of Bioactive and Compatible Polymers*, 32, 1–17.

629 Yang, B., Li, X., Shi, S., Kong, X., Guo, G., Huang, M., Luo, F., Wei, Y., & Zhao, X. (2010).  
630 Preparation and characterization of a novel chitosan scaffold. *Carbohydrate Polymers*, 80,  
631 860-865.

632 Zhao, F., Grayson, W. L., Ma, T., Bunnell, B., & Lu, W. W. (2006). Effects of hydroxyapatite  
633 in 3-D chitosan–gelatin polymer network on human mesenchymal stem cell construct  
634 development. *Biomaterials*, 27, 1859–1867.

635

636 Supplementary data



637

638 Figure 1. Cell distribution through the cross section of Cht/HAp hydrogel and Control after 0,  
639 7 and 14 days of cell culture (c).

640

641

642

643



644

645

646

647

648

649